Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $25.83 Consensus Price Target from Brokerages

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) have been assigned an average recommendation of “Buy” from the seven research firms that are presently covering the stock, MarketBeat reports. Seven analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $25.83.

Several analysts have recently commented on the company. TD Cowen assumed coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating for the company. Guggenheim increased their price objective on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, November 15th.

Insider Activity at Centessa Pharmaceuticals

In related news, insider Gregory M. Weinhoff sold 10,000 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $17.66, for a total transaction of $176,600.00. Following the completion of the sale, the insider now directly owns 183,266 shares of the company’s stock, valued at approximately $3,236,477.56. This trade represents a 5.17 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Saurabh Saha sold 55,000 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $15.77, for a total value of $867,350.00. Following the sale, the chief executive officer now directly owns 429,398 shares of the company’s stock, valued at $6,771,606.46. The trade was a 11.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 404,226 shares of company stock valued at $6,916,914. 11.59% of the stock is owned by insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in Centessa Pharmaceuticals by 47.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after purchasing an additional 826 shares during the period. GAMMA Investing LLC grew its holdings in Centessa Pharmaceuticals by 103.1% during the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after purchasing an additional 1,509 shares during the period. Quarry LP grew its holdings in Centessa Pharmaceuticals by 47.8% during the second quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after purchasing an additional 3,108 shares during the period. Sandia Investment Management LP bought a new position in Centessa Pharmaceuticals during the second quarter valued at $90,000. Finally, Fred Alger Management LLC bought a new position in Centessa Pharmaceuticals during the second quarter valued at $99,000. 82.01% of the stock is owned by institutional investors.

Centessa Pharmaceuticals Stock Up 1.0 %

Shares of NASDAQ:CNTA opened at $16.59 on Wednesday. The business’s 50 day simple moving average is $16.79 and its two-hundred day simple moving average is $15.01. The firm has a market cap of $2.19 billion, a P/E ratio of -10.84 and a beta of 1.53. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. Centessa Pharmaceuticals has a 52-week low of $7.38 and a 52-week high of $18.97.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.05. As a group, research analysts forecast that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.